Back to list

SLE - BMS Paisley Study

University of North Carolina at Chapel Hill


This study is to help patients diagnosed with SLE that is currently on therapy but still having flares. The purpose is to decrease the flares and if subjects are on steroids decrease dose while on study.


Arthritis, Auto Immune Diseases, Joints, Lupus, Skin


Drug or Biologic



18 - 75 years


Study Population

Subject diagnosed with SLE on stable treatment but still having active symptoms


Saira Sheikh
Clinical Assistant Professor
Medicine-UNCP A Rheumatology

For questions, contact:

Julie Walker, CCRC
(919) 843-6619
Visit Website

Recruitment Period End

June 28, 2019


Primary Location
Clinical & Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 75 years

Participant qualification(s) Diagnosed with SLE > 24 weeks before screening Positive ANA or anti-dsDNA or anti-smith Active Skin Rash and/or Joint Pain On SLE meds for at least 12 weeks and stable for 8 weeks Steroids 30mg or less Women are not pregnant/plan to get pregnant or breastfeeding Women and Men must use a required method of contraception

Not eligible if: Diagnosed with active, severe Lupus Nephritis Surgery within last 30 days of screening Cancer within 5 years (except basal cell or squamous cell carcinoma) Call III or IV congestive heart failure Coronary syndrome (ex. myocardial infarction) within 6 months

Number of Visits

    » 16 In person visit(s)

    1 screening, 13 clinic visits, 1 end of treatment visits and 1 end of study/safety follow-up visit

    » 0 Remote visit(s)

Participation Period

52 weeks (around 1 year)


$40 re-loadable card

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.